Company news
Solvonis Therapeutics PLC news in 2025
Solvonis Therapeutics PLC's news releases, calls and decks from 2025, newest first.
Research and Development Update – Q4 2025
December 22, 2025
SVN-015 accepted into US NIDA funded programme
December 3, 2025
Total Voting Rights
October 31, 2025
Appoints global biopharma leader Paul Carter
October 27, 2025
Raises £1.25 Million to Accelerate Programmes
October 16, 2025
Half-year Report
September 30, 2025
Solvonis secures exclusive CNS collaboration
August 28, 2025
Media Coverage: Small Cap Idea profile
August 13, 2025
SVN-SDN-14 PTSD - Positive pre-clinical results
August 12, 2025
Translational Bridging Studies
July 22, 2025
Exercise of warrants
July 18, 2025
Solvonis Chair to speak at Lucid Capital Markets
July 14, 2025
£1m subscription to accelerate AI drug discovery
July 11, 2025
Holding(s) in Company
July 8, 2025
AGM Statement
June 27, 2025
Initiation of Research Coverage
June 26, 2025
Allowance of U.S. patent covering AI-supported CNS
June 23, 2025
Initiation of AI supported CNS drug discovery
June 11, 2025
Synthesis of development candidate for SVN-SDN-014
June 5, 2025
Notice of Annual General Meeting
June 3, 2025
Presentation at Mello2025
May 29, 2025
Completion of the acquisition of Awakn
May 28, 2025
Publication of a Prospectus
May 21, 2025
Result of placing
May 16, 2025
Proposed equity fundraising via ABB
May 15, 2025
Result of General Meeting
April 28, 2025
Proposed acquisition of Awakn approved
April 23, 2025
Final Results for the year ended 31 December 2024
April 16, 2025
Posting of Circular and Notice of General Meeting
April 10, 2025
Engagement of PharmaVentures
April 4, 2025
Positive progress on European Patent Application
March 26, 2025
Update on AWKN-SDN-14 programme
March 18, 2025
Appointment of Non-Executive Director
March 11, 2025
Presentation at PharmaSynergyRx Event
February 25, 2025
Entry into an Arrangement Agreement with Awakn
February 24, 2025
Proactive Investors interview with Chairman
January 30, 2025
Update on Awakn Life Sciences’ R&D Progress
January 27, 2025
Investor Presentation
January 24, 2025
Proactive Investors interview with CEO
January 21, 2025
Interview with CEO
January 15, 2025
Change of Name to Solvonis Therapeutics plc
January 14, 2025
Result of General Meeting and change of name
January 6, 2025